Beacon Bioscience, a provider of medical imaging services for clinical trials and a division of Icon, will change its name to Icon Medical Imaging with effect from 2 April 2007
Following the name change the company will continue to focus on medical imaging services with the same corporate structure, management team and operational processes.
Beacon Bioscience CEO Ted Gastineau, an industry-recognised expert in the application of medical imaging in clinical trials commented: "Our new name emphasises the significance of our position within Icon.
"Medical imaging is an increasingly important factor in the successful conduct of many clinical studies.
"Across the spectrum of trial management services Icon offers, medical imaging has an important place, reflected by the fact that Icon Medical Imaging is one of Icon's core divisions".
Gastineau added, "As we make this change there will be complete continuity in both the work-flow and the experienced professionals who manage client studies".
"Our new name reflects the resources available to us through being part of the broader Icon group and reflects our ongoing commitment to development of innovative imaging services for clients".
As part of the re-branding, the company will adopt a new look and feel consistent with Icon's corporate branding.
In conjunction with the name change, also on 2 April, the imaging solutions provider will begin operating from a newly constructed headquarters, located in Warrington PA, five miles from its current location.
Beacon Bioscience is the provider of medical imaging core lab services to pharmaceutical, biotech and life science clients globally.
The company says its experience and expert guidance allow clients to maximise the use of their medical imaging data, augmenting their current research and development capabilities.
The team at Beacon Bioscience has managed over 250 imaging trials in cancer, cardiovascular, CNS, medical devices and imaging agents.
Icon is a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management and analysis of programmes that support clinical development - from compound selection to Phase I-IV clinical studies.
Icon teams have successfully conducted over 1900 development projects and over 2300 consultancy engagements across all major therapeutic areas.
Icon currently has over 4300 employees, operating from 51 locations in 30 countries.
